Dermatology

The investigational biologic targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells.

A look into nutrition's role in acne care, highlighted by Colleen Sloan, PA-C, RDN.

The primary and all key secondary endpoints were met compared to cream vehicle in the phase 3 DELTA TEEN trial.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The past year saw a number of approvals adding to the toolbox for atopic dermatitis, including new formulations that work in new mechanisms.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the January/February, 2025, issue of Contemporary Pediatrics.

Medical advice was sought on the fifth day of symptoms, and by this time, the child was improving clinically.

The photos in this case were taken soon after the painful and red papules appeared.

Russell Libby, MD, FAAP highlights some key benefits of roflumilast 0.15%, approved in 2024 to treat AD in patients aged 6 years and older.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

"Tapinarof comes in with that mixture of the short-term studies and longer-term studies intermittently, giving us a nice, effective alternative non-steroid for eczema across the ages."

Can you diagnose this healthy, 8.2-lb girl with lesions primarily on her lower lip but also her upper lip, cheeks, and nasolabial folds?

From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024.

Arcutis seeks FDA approval for roflumilast cream 0.05% (ZORVYE) to treat mild to moderate atopic dermatitis in children 2 to 5 years.

According to Galderma, approval is based on positive results from the phase 3 ARCADIA clinical trial program.

"I really hope this becomes a first-line agent that people are comfortable prescribing whether they are in dermatology, pediatric dermatology, or primary care."

In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).

The submission to treat PsO is for children aged 6 years and up while the jPsA submission is to treat children aged 5 years and older.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the final Contemporary Pediatrics journal of the year.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

Once-daily icotrokinra versus placebo demonstrated clinically significant skin clearance in those with moderate-to-severe plaque psoriasis.

The application indication is for adults and pediatric patients aged 12 years and older with CSU whose disease is not adequately controlled with H1 antihistamines.

A target action date for potential approval of prademagene zamikeracel (pz-cel) has been set for April 29, 2025.

A study of over 1 million births in Quebec reveals that pregnant women with hidradenitis suppurativa face increased risks of pregnancy complications and long-term health issues for both themselves and their offspring.